289 related articles for article (PubMed ID: 15352538)
1. New options in the pharmacological management of attention-deficit/hyperactivity disorder.
Olfson M
Am J Manag Care; 2004 Jul; 10(4 Suppl):S117-24. PubMed ID: 15352538
[TBL] [Abstract][Full Text] [Related]
2. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
3. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
Foy JM; Earls MF
Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
[TBL] [Abstract][Full Text] [Related]
4. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
5. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
Bricard C; Boidein F
Encephale; 2001; 27(5):435-43. PubMed ID: 11760693
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
Prince JB
Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
[TBL] [Abstract][Full Text] [Related]
7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
8. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
9. [Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"].
Shmueli D; Gross-Tsur V
Harefuah; 2005 Aug; 144(8):572-6, 597. PubMed ID: 16146157
[TBL] [Abstract][Full Text] [Related]
10. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ;
Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
12. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
13. Psychopharmacology of ADHD in adolescents.
Greydanus DE; Sloane MA; Rappley MD
Adolesc Med; 2002 Oct; 13(3):599-624. PubMed ID: 12270803
[TBL] [Abstract][Full Text] [Related]
14. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
Barner JC; Khoza S; Oladapo A
Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Wigal SB; Chae S; Patel A; Steinberg-Epstein R
Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
[TBL] [Abstract][Full Text] [Related]
16. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
17. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments.
Stein MA
Am J Manag Care; 2004 Jul; 10(4 Suppl):S89-98. PubMed ID: 15352535
[TBL] [Abstract][Full Text] [Related]
18. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications.
Varley CK; Vincent J; Varley P; Calderon R
Compr Psychiatry; 2001; 42(3):228-33. PubMed ID: 11349243
[TBL] [Abstract][Full Text] [Related]
19. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.
Wigal SB; McGough JJ; McCracken JT; Biederman J; Spencer TJ; Posner KL; Wigal TL; Kollins SH; Clark TM; Mays DA; Zhang Y; Tulloch SJ
J Atten Disord; 2005 Aug; 9(1):275-89. PubMed ID: 16371674
[TBL] [Abstract][Full Text] [Related]
20. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.
Waxmonsky JG
Essent Psychopharmacol; 2005; 6(5):262-76. PubMed ID: 16222911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
